GlassScriptPhysician profile
Brett Y Lu
NPI 1649331760
$4,634.75
in general payments reported to CMS, 2019-2025
16 companies · $1,349 in 2025
The $1,349 reported for 2025 was more than what 85% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $336 · 2020: $55.86 · 2021: $530 · 2022: $592 · 2023: $1,053 · 2024: $719 · 2025: $1,349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,104 · Education: $16.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,104.34 |
| Education | $16.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $796.89 | 2021-2025 | |
| Alkermes, INC. | $706.29 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Neurocrine Biosciences, INC. | $527.10 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $453.98 | 2021-2025 | Austedo, Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $409.23 | 2019-2024 | Invega Sustenna, Invega Trinza |
| Acadia Pharmaceuticals INC | $396.61 | 2019-2023 | Nuplazid |
| E.R. Squibb & Sons, L.L.C. | $327.23 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $268.47 | 2019-2024 | Rexulti, Abilify Maintena |
| Axsome Therapeutics, INC. | $257.34 | 2023-2025 | Auvelity |
| Eisai INC. | $118.88 | 2024 | |
| Lundbeck LLC | $96.76 | 2019-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $76.46 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $63.14 | 2022-2024 | Caplyta |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $61.25 | 2023-2025 | Rexulti |
| Allergan, INC. | $42.26 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $32.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Lu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.